

11-07-00
CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"EXPRESS MAIL" MAILING LABEL NUMBER EM474053151US
DATE OF DEPOSIT November 6, 2000
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE BY
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, D.C. 20231



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address Only: Assistant Commissioner
for Patents
Washington, D.C. 20231

Case Docket No. AM100151 01

Roxanne L. Kelly

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

Roxanne L. Kelly
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Sir:

Transmitted herewith for filing is the patent application of

Inventor: Wayne E. Childers et al.

For: Branched Adamantyl and Noradamantyl Aryl- and Aralkylpiperazines
with Serotonin 5-HT1A Activity

This application is a:

- ☒ New Application ☐ CIP Application
- ☐ Divisional Application ☐ Continuation Application
of prior application No. . The entire disclosure of the prior
application, from which a copy of the oath or declaration is supplied, is
considered as being part of the disclosure of the accompanying application
and is hereby incorporated by reference.

Enclosed are:

0 sheets of drawing.

- ☐ Information Disclosure Statement.
- ☐ Preliminary Amendment.
- ☐ Signed statement attached deleting inventor(s) named in the prior application

CLAIMS AS FILED				
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) BASIC FEE \$710.00
TOTAL CLAIMS	38 -20 =	18	x 18.00	\$324.00
INDEPENDENT CLAIMS	4 -3 =	1	x 80.00	\$80.00
MULTIPLE DEPENDENT CLAIMS	0	0	x 270.00	0
TOTAL FILING FEE				\$1114.00

- ☒ Please charge American Home Products Corporation Deposit Account No. 01-1425
in the amount of \$ 1114.00 . Two additional copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16
and 1.17 which may be required during the entire pendency of this application to
American Home Products Corporation Deposit Account No. 01-1425.

Arnold S. Milowsky
Arnold S. Milowsky
Reg. No. 35,288
November 6, 2000

JC954 U.S. PRO
09/706683
11/06/00

- 1 -

5 **BRANCHED ADAMANTYL AND NORADAMANTYL ARYL- AND**
 ARALKYLPIPERAZINES WITH SEROTONIN 5-HT_{1A} ACTIVITY

 This application claims the benefit of U.S. Provisional Application No.
60/228,820, which was converted from U.S. Patent Application No. 09/439,798, filed
10 November 12, 1999; and U.S. Provisional Application No. Not Yet Known, filed
November 18, 1999, which was converted from U.S. Patent Application No.
09/442,981, pursuant to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

 This invention relates to novel branched adamantyl, noradamantyl aryl and
15 aralkylpiperazines having serotonin 5-HT_{1A} activity. More particularly, the present
invention relates to compounds and methods using them to provide neuroprotection
and prevent, inhibit or limit processes of neurodegeneration in mammals.

Introduction

20 Compounds having selective agonist and partial agonist activity at the 5-HT_{1A}
receptor have established a presence in the marketplace as effective anxiolytic agents
(buspirone, Buspar®, US Patent 3,717,634). Evidence generated over the past 20
years supports the hypothesis that 5-HT_{1A} agonists and partial agonists may find use
25 in the treatment of several diseases such as anxiety, depression, schizophrenia, sexual
dysfunction, cognitive deficits resulting from neurodegenerative diseases like
Alzheimer's Disease, nausea and vomiting, sleep disorders, pain, obesity, pain,
addiction/withdrawal and in the treatment of prostate cancer (for recent reviews, see:
Rasmussen, K. and Rocco, V. P., Recent Progress in Serotonin (5-HT)_{1A} Receptor
30 Modulators, In: *Annual Reports in Medicinal Chemistry, Volume 30*, Bristol, J. A.,
ed., Academic Press, New York, **1995**, pp. 1-9; Schaus, J. M. and Bymaster, F. P.,
Latest Developments in Serotonin Receptor Modulation, In: *Annual Reports in*
Medicinal Chemistry, Volume 33, Bristol, J. A., ed., Academic Press, New York,
1998, pp. 21-30).

35 More recent evidence now indicates that 5-HT_{1A} agonists and partial agonists
act in other disease states and conditions by virtue of their ability to inhibit the release
of glutamate. 5-HT_{1A} agonists and partial agonists may be used to treat conditions

- 2 -

- 5 arising from the dysfunction of the glutamate neurotransmitter system or the aberrant release of glutamate.

Glutamate is the predominant neurotransmitter in the central nervous system and it plays an important role in neuroplasticity. As such, excessive extracellular
10 levels of glutamate have been associated with the pathophysiology of both acute neurodegenerative disorders such as stroke, transient ischemic attack and spinal/brain trauma, as well as chronic neurodegenerative disorders such as epilepsy, Alzheimer's Disease, amyotrophic lateral sclerosis, Huntington's Disease, Parkinson's Disease, AIDS dementia and retinal diseases (Holt, W. F. et al., *Glutamate in Health and*
15 *Disease: The Role of Inhibitors*. In: *Neuroprotection in CNS Diseases*. Bar, P. R. and Beal, M. F., ed., Marcel Dekker, Inc., New York **1997**, pp. 87-119; Engelsens, B. A. et al., *Alterations in Excitatory Amino Acid Transmitters in Human Neurological Disease and Neuropathology*. In: *Neurotoxicity of Excitatory Amino Acids*. Guidotti, A., ed., Raven Press Ltd., New York **1990**, pp. 311 - 332; Ince, P. G. et al., *The Role of Excitotoxicity in Neurological Disease*. *Res. Contemp. Pharmacother.* **1997**, *8*,
20 195 - 212; Meldrum, P. S. *The Glutamate Synapse as a Therapeutical Target: Perspective for the Future*. *Prog. Brain. Res.* **1998**, 441 - 458). Compounds which inhibit or attenuate the release of glutamate represent potential neuroprotective agents for the treatment of ischemia resulting from stroke, transient ischemic attack,
25 brain/spinal trauma and fetal hypoxia (Koroshetz, W. J. and Moskowitz, M. A., *Emerging Treatment for Stroke in Humans*. *Trends in Pharmacol. Sci* **1996**, *17*, 227-233; Dunn, C. D. R. *Stroke: Trends, Treatments and Markets*. *Scrip Reports*, PJB Publications, Richmond **1995**). Ischemia can also result from surgery where the blood flow must be halted for a period of time (e.g., cardiac by-pass surgery) due to
30 the resulting anoxia and hypoglycemia (Arrowsmith, J. E. et al., *Neuroprotection of the Brain During Cardiopulmonary Bypass. A Randomized Trial of Remacemide During Coronary Artery Bypass in 171 Patients*, *Stroke* **1998**, *29*, 2357-2362, and references cited within).

- 35 Serotonin 5-HT_{1A} receptors are located in brain areas which are highly sensitive to ischemia, such as the hippocampus and cerebral cortex. Activation of this receptor subtype results in neuronal hyperpolarization and a concomitant inhibition of neuronal activity (DeVry, J. *5-HT_{1A} Receptor Agonists: Recent Developments and*

- 3 -

5 Controversial Issues. *Psychopharmacology* **1995**, 121, 1 - 26). Moreover, it has
been demonstrated that 5-HT_{1A} receptor agonists and partial agonists are able to
attenuate glutamate release, most likely through activation of 5-HT_{1A} receptors
located on glutamatergic terminals (Matsuyama, S. et al., Regulation of Glutamate
Release via NMDA and 5-HT_{1A} Receptors in Guinea Pig Dentate Gyrus. *Brain Res.*
10 **1996**, 728, 175-180) and that a number of 5-HT_{1A} agonists and partial agonists exert
neuroprotective properties *in vivo* (DeVry, J. et al., BAY x 3702, *Drugs of the Future*
1997, 22, 341-349, and references cited within).


15 Therefore, in addition to its well established potential therapeutic applications,
compounds which possesses 5-HT_{1A} agonist or partial agonist activity may be used
as neuroprotective agents as well as a means for treating psychosis.

Preclinical models, neurochemical hypotheses and brain localization have
predicted a number of potential therapeutic targets for serotonin 5-HT_{1A} antagonists
20 as well. These targets include the cognitive deficits observed in Alzheimer's Disease,
anxiety, depression, schizophrenia and urinary incontinence (for a review see
Schechter, L. E. and Kelly, M. G., An Overview of 5-HT_{1A} Receptor Antagonists:
Historical Perspective and Therapeutic Targets, in *Serotonin - Current Drugs ID*
Research Alert **1997**, 2, 299-309).

25

Description of the Invention

In accordance with this invention, there is provided a set of novel compounds,
including their enantiomers, which have activity as serotonin 5-HT_{1A} agonists,
30 partial agonists and antagonists. Compounds of the present invention are described
by the formula I:



- 4 -

5 wherein:

X is selected from $-\text{CH}_2-$ or a chemical bond;

Y is selected from $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_m-$;

10

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

15

R₁ and R₂ are independently selected from the group consisting of aryl or heteroaryl of from 5 – 10 atoms optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆perhaloalkyl, OR₃, or C₁-C₆ perhaloalkoxy;

20

R₃ is selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆-C₁₀ aryl, mono or bicyclic heteroaryl, C₇-C₁₄ aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, -NH₂, -NO₂, -OH, alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆perhaloalkyl, C₁-C₆ alkoxy, and C₁-C₆ perhaloalkoxy;

25

the optical isomers;

and the pharmaceutically acceptable salts thereof.

30


The term C₆-C₁₀ aryl includes phenyl and naphthyl. Monocyclic heteroaryl means a 5-6 membered heteroaryl group having from 1-3 heteroatoms selected independently from N, O, and S, such as pyridine, pyrrole, thiophene, furan, imidazole, oxazole, pyrimidine, pyridazine, pyrazine, thiazole and oxathiazole. Bicyclic heteroaryl includes phenyl fused to a monocyclic 5-6 membered heteroaryl group or a 5-6 membered heteroaryl group fused to another 5-6 membered heteroaryl group, including, but not limited to indole, quinoline, isoquinoline, benzofuran, benzodioxan, benzothiophene, benzimidazole, naphthyridine, and imidazopyridine.

35

- 5 -

- 5 The term C_7-C_{14} aralkyl means a C_1-C_4 alkyl group having a phenyl or naphthyl group as a substituent, and the term heteroaralkyl means a C_1-C_4 alkyl group having a mono or bicyclic heteroaryl group as defined above as a substituent.

Among the preferred compounds of this invention are those of the formula:



Y is selected from $-(CH_2)_m-$ or $-(CH_2)-O-(CH_2)-$;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-
15 C_1-C_6 alkyl, -CN, -NO₂, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6
20 C_6 perhaloalkyl or C_1-C_6 perhaloalkoxy;


R_2 is selected from phenyl, naphthyl, piperazinyl, pyridine, thiophene, furan,
imidazole, oxazole, pyrrole, pyrimidine, pyridazine, pyrazine, thiazole or oxathiazole;

25 the optical isomers;

and the pharmaceutically acceptable salts thereof.

Further preferred compounds of this invention are those of the formula:

- 6 -



5

Y is selected from -CH₂-;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

10

R₁ is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

R₂ is phenyl or pyrimidinyl;

the optical isomers or a pharmaceutically acceptable salt thereof.

15

Optical isomers of the invention compounds can be selectively synthesized or separated using conventional procedures known to those skilled in the art of organic synthesis.

20

The pharmaceutically acceptable salts of the invention compounds include the conventional acid addition salts which are formed from an invention compound and a pharmaceutically acceptable organic or inorganic acid. The acid addition salts include, but is not limited to, the acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, dodecylsulfate, ethanesulfonate, fumarate, glycerophosphate, phosphate, hemisulfate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, nicotinate, oxalate, pamoate, pectinate, pivalate, propionate, succinate, tartrate, and tosylate. Also the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, dialkyl sulfates, long chain halides such as lauryl bromide, aralkyl halides like benzyl and phenethyl bromides.

25

30

Methods of treatment of this invention include those glutamate-mediated maladies wherein inhibition of glutamate release is desirable. These methods may

- 7 -

5 be characterized as methods for inhibiting or limiting neuronal glutamate release in a mammal, the method comprising administering to the mammal, preferably to a human patient, a pharmaceutically effective amount of a compound of this invention, or a pharmaceutically effective salt thereof.

10 As such, these compounds may be useful in the treatment of several diseases such as anxiety, depression, schizophrenia, sexual dysfunction, cognitive deficits resulting from neurodegenerative diseases including Alzheimer's Disease, nausea and vomiting, epilepsy, sleep disorders, obesity, pain, addiction/withdrawal, urinary incontinence, prostate cancer, and ischemia resulting from acute stroke, transient
15 ischemic attack, head and spinal trauma, fetal hypoxia, neuronal hypoxia, cardiac surgery or any other surgical technique which requires halting the blood flow for a period of time.

The methods of this invention are also useful in inhibiting or limiting the
20 chronic neurodegenerative actions associated with Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, epilepsy, amyotrophic lateral sclerosis, AIDS dementia as well as retinal diseases. Therefore, this invention also comprises methods of treatment for each of these maladies, the methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of this
25 invention, or a pharmaceutically acceptable salt thereof.

The compounds of this invention may also be used in the mediation or inhibition of glutamate activity associated with the maladies known as chronic, neuropathic or persistent pain, including its actions in fibromyalgia, postherpetic
30 neuralgia, reflex sympathetic dystrophy, diabetic peripheral neuropathy, etc.

Of particular interest is methods of using the compounds of this invention to treat, prevent, limit, inhibit, delay or alleviate neurodegeneration in a mammal, the methods comprising administering to a mammal in need thereof a pharmaceutically
35 effective amount of a compound of this invention, or a pharmaceutically acceptable salt thereof. These methods include those in which the neurodegenerative disease or disorder is acute or chronic. Included are those instances in which the neurodegeneration results from stroke, including thromboembolic stroke, focal


- 8 -

5 ischemia, global ischemia and tranient ischemic attack. Also included are those neurodegenerative disorders such as ischemia resulting from a surgical technique involving prolonged halt of blood flow to the brain, head or spinal trauma, or hypoxia, including fetal hypoxia.

10 For their ability to inhibit, prevent or limit further neural degradation in the hypoxic and ischemic events of the maladies described above, the methods of treatment of this invention may also be characterized as methods for providing or inducing neuroprotection in a mammal, as their activity reduces or inhibits the glutamate-mediated or glutamate-related degeneration which would naturally occur.

15 The compound of formula I can be prepared by conventional chemical methods which are well known to those skilled in the art of chemistry using chemicals that are either commercially available or readily prepared following standard literature procedures. For example, the compounds may be synthesized in
20 four steps (Scheme 1) starting from the appropriate phenylalanine, phenylglycine or heteroaryl-substituted alanine or heteroaryl-substituted glycine which has been protected on the nitrogen atom with a suitable protecting group such as the t-butoxycarbonyl group (BOC). This material is coupled to the appropriately substituted arylpiperazine or aralkyl piperazine using a suitable coupling catalyst,
25 such as dicyclohexylcarbodiimide (DCC) to afford compound 1. Removal of the BOC group under acidic conditions followed by reduction using an appropriate reducing agent such as lithium aluminum hydride or a borane complex leads to the penultimate intermediate 3. Subsequent acylation of 3 with a suitable acylating agent such as adamantane-1-carboxylic acid chloride or noradamantyl-3-carboxylic acid
30 chloride gives compounds of formula I, which are isolated as acceptable salts.

- 9 -




Scheme 1

In cases where the R_2 grouping is not compatible with the reductive conditions required for the conversion of intermediate **2** to intermediate **3**, it may be introduced after the reduction of the amide by initially protecting the NH group of the piperazine with a benzyl moiety (Scheme 2). This benzyl group can then be removed under catalytic hydrogenation conditions and the R_2 group incorporated into the molecule to give the final products.

The starting materials required for the synthesis of the compounds of formula I are either commercially available or readily obtained using conventional methods described in the literature. The preparative method described above is not meant to be restrictive but only illustrative since other methods of preparing the compounds of formula I may be obvious to those skilled in the art of chemistry. For example, while numerous, N-protected amino acids are commercially available, the protecting group may alternatively be introduced onto an amino acid using conventional methods which are well described in the literature. Other protecting groups such as carbobenzyloxy (CBZ) may be employed to protect the nitrogen grouping in the first step of the synthesis and many other coupling catalysts may serve to effect the reaction. Exact reagents required to de-protect the amine group of intermediate **1** once the coupling has been effected will depend on the protecting group used and the

- 10 -

5 substituents present in the molecule. Other reducing agents besides LAH or borane may serve to accomplish the reduction of intermediate **2**. Finally, the introduction of the acyl-adamantyl or acyl-noradamantyl group may be accomplished according to the general method described in Scheme 1 using one of many possible acylating derivatives, which include but are not limited to acid halides (e.g., acid chloride),
 10 anhydrides and activated esters and amides or through the use of adamantyl- or noradamantyl carboxylic acid and an appropriate coupling catalyst.



Scheme 2

15

Since numerous chirally pure amino acids and protected amino acids are either commercially available or known in the literature, the pure optical isomers of the compounds of formula I may be obtained stereospecifically by beginning the
 20 synthesis with chirally pure starting materials. Alternatively, the optical isomers of the compounds of formula I may be obtained by conventional separation methods which are well known to those skilled in the art of synthetic chemistry. These

- 5 methods include but are not restricted to crystallization of a mixture of diastereomeric salts, enzymatic resolution, chromatography of one of the intermediates or the final product on a chiral column, or formation and separation of a diastereomeric mixture followed by conversion back to the chirally pure material.
- 10 The following examples are included for illustrative purposes only and are not intended to be considered as limiting to this disclosure in any way.

5

Example 1

(R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

10

(R)-Phenylalanine-N-[4-(phenylmethyl)-1-piperizinyl]carboxamide

Dihydrochloride. D-Phenylalanine-N-t-butoxycarboxamide (13.25 g, 50 mmol) and 1-benzylpiperazine (8.8 g, 50 mmol) were dissolved in 125 mL of dry dichloromethane and cooled in an ice bath. The stirred mixture was then treated with a solution of diethylcyanophosphonate (8.97 g, 55 mmol) in 50 mL of dry dichloromethane over a period of 45 minutes. A solution of N-methylmorpholine (5.55 g, 55 mmol) in 50 mL of dry dichloromethane was then added over a period of one hour. The resulting reaction mixture was stirred overnight, during which time it came up to room temperature. The solution was then washed with 100 mL of 10% aqueous potassium carbonate, dried over anhydrous sodium sulfate, and concentrated on a rotary evaporator to yield 26 g of the crude intermediate BOC-(R)-phenylalanine-N-(4-benzyl-1-piperazinyl)carboxamide. This oil was dissolved in 200 mL of dichloromethane and treated with a 4.6 N solution of HCl in ethyl acetate (350 mL). After stirring at room temperature for one hour (at which time CO₂ evolution ceased), 250 mL of dry diethyl ether was added. The desired dihydrochloride salt of (R)-phenylalanine-N-[(4-phenylmethyl)-1-piperazinyl]-carboxamide (18.9 g, 95%) precipitated and was isolate by filtration, washed with diethyl ether, and dried in vacuo: mp = 140 - 150°C; [α -D]²⁵ = -3.7° (c = 1, MeOH); MS *m/z* = 323 (M⁺).

30

(R)-[1-(Phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine. A

solution of (R)-phenylalanine-N-[(4-phenylmethyl)-1-piperazinyl]carboxamide dihydrochloride (18.8 g, 47.4 mmol) in 230 mL of 1 M borane/tetrahydrofuran was refluxed with stirring for four hours under a nitrogen atmosphere. The resulting mixture was cooled in an ice bath and quenched by slow addition of 150 mL of 2N aqueous HCl. The resulting mixture was then refluxed with stirring overnight. The tetrahydrofuran was removed under reduced pressure. The filtrate was washed with five 50 mL portions of dichloromethane and then made strongly basic with 50% aqueous sodium hydroxide solution. The resulting alkaline mixture was then

35

- 13 -

5 extracted with three 100 mL portions of dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate and concentrated on a rotary evaporator to yield the desired (R)-[1-(phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine (17.1 g, 95%) as a yellow oil which was used without further purification. A sample of this oil was converted to the trihydrochloride sesquihydrate salt with ethyl acetate/HCl for characterization: m.p. = 183 – 185 C; $[\alpha\text{-D}]^{25} = -27.7$ (c= 1, MeOH); MS $m/z = 309$ (M^+).

Analysis for $C_{20}H_{25}N_3O \cdot 3 HCl \cdot 1\frac{1}{2} H_2O$

Calculated: C: 53.83; H: 7.40; N: 9.42

15 Found: C: 54.22; H: 7.11; N: 9.24.

(R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]-ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

20 To an ice-cooled solution of 1-adamantanecarboxylic acid (5.1 g, 50 mmol) and (R)-[1-(phenylmethyl)-2-[(4-phenylmethyl)-1-piperazinyl]ethyl]amine (9.6 g, 25 mmol) in 60 mL of dry dichloromethane was added, with stirring, diethylcyanophosphonate (4.1 g, 25 mmol) over a period of thirty minutes. Upon completed addition, N-methylmorpholine (2.53 g, 25 mmol) was added and the resulting mixture was stirred overnight during which time it came up to room temperature. The reaction mixture
25 was then washed with 100 mL of 10% aqueous potassium carbonate solution followed by 100 mL of water. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated on a rotary evaporator. The desired product was isolated by chromatography on silica gel using a gradient of ethyl acetate and hexane and then converted to its dihydrochloride dihydrate salt (6.30 g, 44%) with HCl/ethyl
30 acetate: mp = 261-263°C; $[\alpha\text{-D}]^{25} = -12.5^\circ$ (c=1, MeOH); CIMS $m/z = 472$ (MH^+).

Analysis for $C_{31}H_{41}N_3O \cdot 2 HCl \cdot 2 H_2O$

Calculated: C: 64.12; H: 8.16; N: 7.24

Found: C: 63.92; H: 8.30; N: 6.90.

35

- 14 -

5

Example 2

(S)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

10

Beginning with L-phenylalanine-N-t-butoxycarboxamide, (S)-N-[1-(phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 1. It was isolated as its dihydrochloride dihydrate salt in 9% overall yield: mp 263 - 266°C; $[\alpha]_D^{25} = +11.3$ (c=1.03, MeOH); CIMS $m/z = 472$ (MH⁺).

15

Analysis for C₃₁H₄₁N₃O • 2 HCl • 2 H₂O

Calculated: C: 64.12; H: 8.16; N: 7.24

20

Found: C: 64.13; H: 7.86; N: 7.27.

Example 3

25

(R)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Hemihydrate

30

35

The compound of Example 1 (4.5 g, 7.84 mmol) was hydrogenated over 10% Pd/C (1 g) in 200 mL of ethanol on a Parr shaker at a pressure of 36 psi overnight. The catalyst was removed by filtration through Celite and the mixture concentrated on a rotary evaporator to yield the crude (R)-N-[1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide (2.8 g) as an oil. This oil was dissolved in 50 mL of dry dimethylformamide. To the stirred solution was added 2-chloropyrimidine (1.05 g, 9.2 mmol), anhydrous potassium carbonate (12.4 g, 90 mmol), and triethylamine (1 mL), and the resulting mixture was heated at 70°C overnight. The DMF was removed on a rotary evaporator and the residue was triturated with water. The resulting precipitate was washed with water, air-dried, and recrystallized from 50% aqueous methanol to yield the desired compound as a hemihydrate: mp 172-175°C;

- 15 -

5

$[\alpha\text{-D}]^{25} = -9.7^\circ$ ($c=1.07$, MeOH); CIMS $m/z = 460$ (MH^+).

Analysis for $\text{C}_{28}\text{H}_{35}\text{N}_5\text{O} \cdot \frac{1}{2} \text{H}_2\text{O}$

Calculated: C: 71.76; H: 8.17; N: 14.95

Found: C: 71.90; H: 8.02; N: 14.82.

10

Example 4

(S)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide

15

Beginning with the compound of Example 2, (S)-N-[1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 3. It was isolated in 78% overall yield: mp 172 - 175°C; $[\alpha\text{-D}]^{25} = +7.20$ ($c=1.03$, MeOH); CIMS $m/z = 460$ (MH^+).

20

Analysis for $\text{C}_{28}\text{H}_{37}\text{N}_5\text{O}$

Calculated: C: 73.17; H: 8.11; N: 15.24

Found: C: 72.87; H: 7.90; N: 15.00.

25

Example 5

(R)-N-[1-((Phenylmethoxy)methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

30

Beginning with D-O-benzylserine-N-t-butoxycarboxamide, (R)-N-[1-((phenylmethoxy)-methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide was prepared using a synthetic sequence identical to that described for the synthesis of Example 1. It was converted to its dihydrochloride dihydrate salt with ethyl acetate/HCl and isolated in 5% overall yield: mp 140 - 142°C; $[\alpha\text{-D}]^{25} = +19.0$ ($c=0.98$, MeOH); CIMS $m/z = 502$ (MH^+).

35

- 16 -

5 Analysis for $C_{32}H_{43}N_3O_2 \cdot 2 HCl \cdot 2 H_2O$
Calculated: C: 62.94; H: 8.08; N: 6.88
Found: C: 62.74; H: 8.07; N: 6.86.

Example 6

10 **(R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate**

15 **(R)-[1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester.** To a 0°C solution of D-phenylalanine-N-t-butoxy-carboxamide (10.0 g, 37.7 mmol), 1-hydroxybenzotriazole (8.66 g, 64.1 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.20 g, 37.7 mmol) in dry dimethylformamide (50 mL) under a nitrogen atmosphere, was added 1-(2-methoxyphenyl)-piperazine (9.50 g, 41.5 mmol), followed by N-methylmorpholine (7.62 g, 75.4 mmol). The resulting mixture was stirred under nitrogen overnight, during which time it came up to room temperature. The reaction mixture was diluted with ethyl acetate and then washed with 0.1 N aqueous HCl, saturated aqueous sodium bicarbonate and saturated sodium chloride solution. The combined organic layers dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired product (16.57 g, 99% yield) as a yellow oil which was pure enough to use without further purification: $[\alpha-D]^{25} = -9.0$ (c=1, MeOH); MS $m/z = 439$ (M^+).

25 Analysis for $C_{25}H_{33}N_3O_4$
30 Calculated: C: 68.31; H: 7.57; N: 9.56
Found: C: 68.09; H: 7.17; N: 9.46.

35 **(R)-1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethylamine.** A solution of (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester (16.37 g, 37.3 mmol) in a mixture of dioxane (150 mL)/4N aqueous HCl (150 mL) was stirred at room temperature for 6 hours. The reaction mixture was then concentrated under reduced pressure and the aqueous mixture was extracted with diethyl ether. The combined

- 17 -

5 organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]amine hydrochloride (14.0 g, 100% yield) as an off-white solid, which was used in the next step without further purification.

10 To a solution of (R)-[1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]amine hydrochloride (14 g, 37.3 mmol) and triethylamine (7.53 g, 74.6 mmol) in anhydrous tetrahydrofuran (150 mL) under a nitrogen atmosphere was added, dropwise, a 1M solution of borane in tetrahydrofuran (131 mL, 130.6 mmol). The resulting mixture was stirred at reflux for three hours, then
15 allowed to stir at room temperature overnight. The resulting mixture was treated with 2N aqueous HCl (300 mL) for two hours and the layers were separated. The acidic aqueous layer was washed with ethyl acetate, made basic with 50% aqueous sodium hydroxide, and extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over anhydrous
20 sodium sulfate and concentrated under reduced pressure. The desired product (11.0 g, 91.0% yield) was isolated as an off-white solid: m.p. = 95 – 97°C;

$[\alpha\text{-D}]^{25} = -36.7$ (c=1, MeOH); FAB MS m/z = 326 (MH⁺).

Analysis for C₂₀H₂₇N₃O

25 Calculated: C: 73.80; H: 8.37; N: 12.77

Found: C: 73.15; H: 8.34; N: 12.68

(R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate. To a solution of
30 (R)-1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]amine (0.25 g, 0.77 mmol) and triethylamine (0.16 g, 1.54 mmol) in anhydrous dichloromethane (15 mL) under a nitrogen atmosphere at 0 °C was added a solution of 1-adamantane-carboxylic acid chloride (0.17 g, 0.84 mmol) in dichloromethane (5 mL). The resulting solution was allowed to stir overnight under nitrogen, during which time it
35 came up to room temperature. The reaction mixture was then concentrated under reduced pressure, diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The desired product was purified by flash chromatography on silica gel

- 18 -

- 5 (ethyl acetate/hexane) and converted to its hemifumarate hemihydrate salt with fumaric acid/ethanol to yield 0.30 g (71% yield) as a white solid: m.p. = 153 – 155°C; $[\alpha\text{-D}]^{25} = -9.0$ (c=1, MeOH); MS m/z = 487 (M+).

Analysis for $\text{C}_{31}\text{H}_{41}\text{N}_3\text{O}_2 \cdot \frac{1}{2} \text{C}_4\text{O}_4 \cdot \frac{1}{2} \text{H}_2\text{O}$

10 Calculated: C: 71.45; H: 8.00; N: 7.57

Found: C: 71.26; H: 8.05; N: 7.42.

Example 7

15 **(S)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hydrate**

This compound was prepared using an identical synthetic sequence to that described for Example 6 starting with L-phenylalanine-N-t-butoxy-carboxamide. The overall yield was 61% and the compound (an off-white solid) was isolated as the hemifumarate hydrate salt: m.p. = 157 – 159°C; $[\alpha\text{-D}]^{25} = +9.5$ (c=1, MeOH); FAB MS m/z = 488 (MH⁺).

Analysis for $\text{C}_{31}\text{H}_{41}\text{N}_3\text{O}_2 \cdot \frac{1}{2} \text{C}_4\text{O}_4 \cdot \text{H}_2\text{O}$

25 Calculated: C: 70.31; H: 8.05; N: 7.45

Found: C: 70.21; H: 8.04; N: 7.11.

In Vitro Data

30 Affinity for the serotonin 5-HT_{1A} receptor was established by assaying the test compound's ability to displace [³H]-8-OH-DPAT from its binding site on the receptor complex in rat hippocampal membrane homogenates according to the method described in US Patent 5,482,940. The compounds of this invention displayed high affinity for the 5-HT_{1A} receptor, as exemplified by the data given in Table 1.

35 Some of the compounds of this invention displayed serotonin 5-HT_{1A} agonist activity, as measured by the test compounds's ability to stimulate the binding of

- 19 -

- 5 [35S]-GTPγS to the 5-HT_{1A} receptor-G protein complex in CHO cells stably transfected with the human 5-HT_{1A} receptor following a variation of the procedure described by Lazerino and Birdsall (*Br. J. Pharmacol.*, **109**, 1120 (1993)). Data are given in Table 1. Data are presented as the percent of

10

Table 1

Example	5-HT _{1A} Affinity (IC ₅₀)	5-HT _{1A} Agonist Activity (GTPγS)		5-HT _{1A} Antagonist Activity (GTPγS)	
		% Agonist Activity	EC ₅₀	% Antagonist Activity	EC ₅₀
1	2.3 nM			100%	36 nM
2	0.70 nM	51%	21 nM		
3	0.43 nM	100%	2.0 nM		
4	1.0 nM	99%	2.4 nM		
5	62 nM	49%	77 nM		
6	0.21 nM	76%	2.0 nM		
7	0.70 nM	85%	2.0 nM		

- agonist activity observed relative to the effect obtained with the 5-HT_{1A} full agonist 8-OH-DPAT and the corresponding EC₅₀ value. As can be seen from Table 1, the
15 compounds of this invention are potent 5-HT_{1A} ligands which display agonist and partial agonist activity in the GTPγS assay.

- Some of the compounds of this invention displayed serotonin 5-HT_{1A} antagonist activity, as measured by the test compound's ability to block the
20 stimulation of the binding of [35S]-GTP S to the 5-HT_{1A} receptor-G protein complex induced by the 5-HT_{1A} full agonist 8-OH-DPAT in CHO cells stably transfected with the human 5-HT_{1A} receptor following a variation of the procedure described by Lazerino and Birdsall (*Br. J. Pharmacol.*, 109, 1120 (1993)). Data are
25 given in Table 1. As can be seen from Table 1, some of the compounds of this invention are potent 5-HT_{1A} ligands which display antagonist activity in the GTP S assay.

- 20 -

5 These activities make the compounds of this invention useful for the treatment
of several diseases such as anxiety, depression, schizophrenia, sexual dysfunction,
cognitive deficits resulting from neurodegenerative diseases like Alzheimer's
Disease, nausea and vomiting, epilepsy, sleep disorders, obesity, pain,
addiction/withdrawal, urinary incontinence, prostate cancer, and ischemia resulting
10 from acute stroke, transient ischemic attack, head and spinal trauma, fetal hypoxia,
cardiac surgery or any other surgical technique which requires halting the blood flow
for a period of time, and chronic neurodegenerative diseases such as Alzheimer's
Disease, Huntington's Disease, Parkinson's Disease, amyotrophic lateral sclerosis,
AIDS dementia as well as retinal diseases.

15 **Pharmaceutical Composition**

20 This invention also comprises pharmaceutical compositions comprising
pharmaceutically effective amounts of one or more compounds of this invention, or a
pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable
carriers or excipients. The pharmaceutically effective amount of these compounds
will be understood to be an amount which provides an effective degree of
neuroprotection or treats, inhibits or limits the neurodegeneration in question. In
humans, a daily dosage of from about 100 mg to about 1,500 mg per day may be
25 administered, preferably between about 300 mg and about 1,200 mg per day, more
preferably between about 500 mg and 1,000 mg per day. These dosages may be
administered in a single administration or divided into multiple doses for sequential
administration.

30 The compounds of the present invention may be administered orally or
parentally, neat or in combination with conventional pharmaceutical carriers.
Applicable solid carriers can include one or more substances which may also act as
flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants,
compression aids, binders, tablet-disintegrating agents or encapsulating materials. In
35 powders, the carrier is a finely divided solid which is in admixture with the finely
divided active ingredient. In tablets, the active ingredient is mixed with a carrier
having the necessary compression properties in suitable proportions and compacted in
the shape and size desired. The powders and tablets may contain up to 99% of the
active ingredient. Suitable solid carriers include, for example, calcium phosphate,

- 21 -

5 magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl
cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes
and ion exchange resins. Liquid carriers may be used in preparing solutions,
suspensions, emulsions, syrups and elixirs. The active ingredient of this invention
10 can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as
water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
The liquid carrier can contain other suitable pharmaceutical additives such as
solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents,
suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-
15 regulators. Suitable examples of liquid carriers for oral and parenteral administration
include water (particularly containing additives as above, e.g., cellulose derivatives,
preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric
alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g.,
fractionated coconut oil and arachis oil). For parenteral administration, the carrier
20 can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid
carriers are used in sterile liquid form compositions for parenteral administration.
Liquid pharmaceutical compositions, which are sterile solutions or suspensions can
be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection.
Sterile solutions can also be administered intravenously. Oral administration may be
25 either in liquid or solid composition form. Preferably, the pharmaceutical
compositions containing the present compounds are in unit dosage form, e.g., as
tablets or capsules. In such form, the composition is sub-divided in unit dosages
containing appropriate quantities of the active ingredients. The unit dosage forms can
be packaged compositions, for example, packaged powders, vials, ampoules, prefilled
syringes or sachets containing liquids. Alternatively, the unit dosage form can be, for
30 example, a capsule or tablet itself, or it can be the appropriate number of any such
compositions in package form. The therapeutically effective dosage to be used in the
treatment of a specific disease or condition must be subjectively determined by the
attending physician. The variables involved include the specific condition(s) being
treated and the size, age and response pattern of the patient.

35


The present invention may be embodied in other specific forms without
departing from the spirit and essential attributes thereof and accordingly, reference

Year	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1995	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100																

5

What is Claimed:

1. A compound of the formula (I):



10

wherein:

X is selected from $-\text{CH}_2-$ or a chemical bond;

Y is selected from $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)-\text{O}-(\text{CH}_2)-$;

m is selected from the integer 0 or 1;

15

n is selected from the integer 0 or 1;

R_1 and R_2 are independently selected from the group consisting of aryl or

heteroaryl of from 5 – 10 atoms optionally substituted with F, Cl, Br, I, $-\text{OH}$, $-\text{NH}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2-\text{C}_1-\text{C}_6$ alkyl, $-\text{CN}$, $-\text{NO}_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perhaloalkyl, OR_3 , or C_1-C_6 perhaloalkoxy;


20

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_6-C_{10} aryl, mono or bicyclic heteroaryl, C_7-C_{14} aralkyl, and mono or bicyclic heteroaralkyl, where the aryl or heteroaryl group is optionally substituted with one to three substituents independently selected from the group consisting of F, Cl, Br, I, CN, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{OH}$, alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 perhaloalkyl, C_1-C_6 alkoxy, and C_1-C_6 perhaloalkoxy; and the optical isomers or a pharmaceutically acceptable salt thereof.

25

2. A compound of Claim 1 having the formula:

- 24 -



5

wherein:

Y is selected from $-(CH_2)_m-$ or $-(CH_2)-O-(CH_2)-$;


m is selected from the integer 0 or 1;

10 n is selected from the integer 0 or 1;

R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

15 R_2 is selected from phenyl, naphthyl, piperazinyl, pyridine, thiophene, furan, imidazole, oxazole, pyrrole, pyrimidine, pyridazine, pyrazine, thiazole or oxathiazole; and the optical isomers or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 1 of the formula:



20

wherein:

Y is selected from $-CH_2-$;

m is selected from the integer 0 or 1;

n is selected from the integer 0 or 1;

25 R_1 is phenyl optionally substituted with F, Cl, Br, I, -OH, -NH₂, -CO₂H, -CO₂-C₁-C₆ alkyl, -CN, -NO₂, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perhaloalkyl or C₁-C₆ perhaloalkoxy;

R_2 is phenyl or pyrimidinyl;

- 25 -

5 and the optical isomers or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

10

5. A compound of Claim 1 which is (R)-Phenylalanine-N-[4-(phenylmethyl)-1-piperizinyl]carboxamide Dihydrochloride.

6. A compound of Claim 1 which is (R)-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]amine.

15

7. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

20

8. A compound of Claim 1 which is (S)-N-[1-(Phenylmethyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate.

9. A compound of Claim 1 which is (R)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide Hemihydrate

25

10. A compound of Claim 1 which is (S)-N-[1-(Phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1^{3,7}]-decane-1-carboxamide

30

11. A compound of Claim 1 which is (R)-N-[1-((Phenylmethoxy)methyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]tricyclo-[3.3.1.1^{3,7}]-decane-1-carboxamide Dihydrochloride Dihydrate

35

12. A compound of Claim 1 which is (R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate.

- 26 -

5

13. A compound of Claim 1 which is (R)-[1-(Phenylmethyl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxo-ethyl]-carbamic acid tert-butyl ester.

10 14. A compound of Claim 1 which is (R)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hemihydrate.

15 15. A compound of Claim 1 which is (S)-Adamantane-1-carboxylic acid [1-(phenylmethyl)-2-[4-(2-methoxyphenyl)-piperazinyl]ethyl]-amide Hemifumarate Hydrate.

20 16. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound of Claim 1 or a pharmaceutical salt thereof, to a patient in need of said treatment.

17. The method of Claim 16 wherein the neurodegenerative disorder is chronic.

25 18. The method of Claim 16 wherein the neurodegenerative disorder is Alzheimer's Disease.

19. The method of Claim 16 wherein the neurodegenerative disorder is Huntington's Disease.

30 20. The method of Claim 16 wherein the neurodegenerative disorder is Parkinson's Disease.

21. The method of Claim 16 wherein the neurodegenerative disorder is AIDS dementia.

35

- 27 -

5 22. The method of Claim 16 wherein the neurodegenerative disorder is
retinal disease.

 23. The method of Claim 16 wherein the neurodegenerative disorder is
epilepsy.

10

 24. The method of Claim 16 wherein the neurodegenerative disorder is
amyotrophic lateral sclerosis.

15

 25. The method of Claim 16 wherein the neurodegenerative disorder is
acute.

 26. The method of claim 25 wherein the neurodegenerative disorder is
stroke.

20

 27. The method of claim 26 wherein stroke is acute thromboembolic
stroke.

 28. The method of claim 26 wherein stroke is focal ischemia.

25

 29. The method of claim 26 wherein stroke is global ischemia.

 30. The method of claim 26 wherein stroke is transient ischemic attack.

30 31. The method of Claim 16 wherein the neurodegenerative disorder is
ischemia resulting from a surgical technique involving prolonged halt of blood flow
to the brain.

 32. The method of claim 16 wherein the neurodegenerative disorder is
head trauma.

- 28 -

5

33. The method of claim 16 wherein the neurodegenerative disorder is spinal trauma.

34. The method of claim 16 wherein the neurodegenerative disorder is
10 hypoxia.

35. The method of claim 34 wherein the hypoxia is fetal hypoxia.

36. A method of neuroprotection comprising administering a
15 therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

37. A method of treating chronic pain comprising administering a
therapeutically effective amount of a compound of Claim 1 or a pharmaceutical salt
20 thereof, to a patient in need of said treatment.


38. The method of Claim 37 wherein the chronic pain is diabetic peripheral neuropathy.

25

5

ABSTRACT OF THE DISCLOSURE

This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection., the compounds having the structure:



15

wherein X is -CH₂- or a bond; Y is -(CH₂)_m- or -(CH₂)-O-(CH₂)-; m 0 or 1; n is 0 or 1; R₁ and R₂ are independently selected from optionally substituted aryl or heteroaryl; the optical isomers and the pharmaceutically acceptable salts thereof.

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Branched Adamantyl and Noradamantyl Aryl- and Aralkylpiperazines with Serotonin 5-HT1A Activity, the specification of which

(check one) _____ is attached hereto.

_____ was filed on _____ as
Application Serial No. _____
and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed
Yes No

(Number) (Country) (Day/Month/Year Filed)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States Provisional Application(s) for Patent listed below:

60/228,820 November 12, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/439,798, filed November 12, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

Not Yet Known November 18, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/442,981, filed November 18, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Pending

(Application Serial No.) (Filing Date) (Status - Patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status - Patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Egon E. Berg, Reg. No. 21,117, of One Campus Drive, Parsippany, New Jersey, 07054; and Rebecca R. Barrett, Reg. No. 35,152; Steven R. Eck, Reg. No. 36,126; Arnold S. Milowsky, Reg. No. 35,288; Michael R. Nagy, Reg. No. 33,432; George Tarnowski, Reg. No. 27,472; all of P.O. Box 8299, Philadelphia, Pennsylvania, 19101; Daniel B. Moran, Reg. No. 41,204 of 401 N. Middletown Road, Pearl River, New York, 10965; and Barbara L. Lences, Reg. No. 41,148, of CN-8000, Princeton, New Jersey, 08543-8000.

Address all telephone calls to Steven R. Eck at telephone number (610) 902-2628.

Address all correspondence to Egon E. Berg, American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, New Jersey, 07054.

Full name of sole or first inventor Wayne E. Childers, Jr.

Inventor's signature Wayne E. Childers, Jr. 10/27/00
Date

Residence 201 Riverwood Drive, New Hope, Pennsylvania, 18938

Citizenship United States of America

Post Office Address Same as residence

Full name of second joint inventor, if any Horace Fletcher, III

Inventor's signature Horace Fletcher, III 11/1/00
Date

Residence 2382 Schaffer Road, Pottstown, Pennsylvania, 19464

Citizenship United States of America

Post Office Address Same as residence

Full name of third joint inventor, if any Magid A. Abou-Gharbia

Inventor's signature *Magid A. Abou-Gharbia* 10/27/00
Date

Residence 26 Hawthorne Drive, Princeton Junction, New Jersey, 08550

Citizenship United States of America

Post Office Address Same as residence

Full name of fourth joint inventor, if any John P. Yardley

Inventor's signature *John P. Yardley* 10/06/00
Date

Residence 154 Hughes Road, King of Prussia, Pennsylvania, 19406

Citizenship United States of America

Post Office Address Same as residence